Using eye imaging and blood tests to detect Alzheimer's early
Multimodal Ophthalmic Imaging and Plasma Biomarkers for the Early Detection of Alzheimer's Disease
Peking University First Hospital · NCT06924359
This study is testing if eye scans and blood tests can help find signs of Alzheimer's disease earlier in people aged 50 and older, whether they have the disease or not.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Ages | 50 Years and up |
| Sex | All |
| Sponsor | Peking University First Hospital (other) |
| Locations | 1 site (Beijing) |
| Trial ID | NCT06924359 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on identifying specific plasma biomarkers and ocular indicators that can aid in the early detection of Alzheimer's disease. Participants aged 50 and older, including those diagnosed with Alzheimer's, mild cognitive decline, subjective cognitive decline, or who are cognitively normal, will undergo multimodal ophthalmic imaging and blood sampling. The study aims to establish a correlation between ocular changes and plasma biomarkers associated with Alzheimer's, potentially leading to earlier diagnosis and intervention.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals aged 50 and older, with a diagnosis of Alzheimer's disease, mild cognitive decline, subjective cognitive decline, or those who are cognitively normal.
Not a fit: Patients with other neurological disorders or systemic diseases that may cause cognitive impairment are unlikely to benefit from this study.
Why it matters
Potential benefit: If successful, this study could enable earlier detection of Alzheimer's disease, allowing for timely interventions that may slow disease progression.
How similar studies have performed: While the approach of using multimodal imaging and plasma biomarkers is promising, it is still relatively novel and has not been extensively tested in previous studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Male or female participants aged ≥ 50 years; * Participants diagnosed with Alzheimer's Disease (AD), mild cognitive decline (MCI), subjective cognitive decline (SCD), or cognitively normal (CN); * Signed informed consent form Exclusion Criteria: * Presence of other neurological disorders and systemic diseases that may cause cognitive impairment; * Inability to cooperate with cognitive assessments; * Refusal to undergo blood sampling.
Where this trial is running
Beijing
- Peking University First Hospital — Beijing, China (RECRUITING)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Alzheimer', s Disease